Steffen Emmert

Prof. Dr. Steffen Emmert

Clinic for Dermatology and Venerology, Rostock University Medical Center, Strempelstr. 13, 18057 Rostock, Germany
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2014 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
FBF. Brehmer
F. Brehmer
HHH.A. Haenssle
H.A. Haenssle
GDG. Daeschlein
G. Daeschlein
RAR. Ahmed
R. Ahmed
SPS. Pfeiffer
S. Pfeiffer
Steffen EmmertSteffen Emmert
Steffen Emmert

Verified
Journal Article
Open access
PDF file
YRYanru Ren
Yanru Ren
LFLu Fan
Lu Fan
SASaid Alkildani
Said Alkildani
Luo LiuLuo Liu
Luo Liu
Steffen EmmertSteffen Emmert
Steffen Emmert
Mike BarbeckMike Barbeck
Mike Barbeck
Guided bone regeneration (GBR) has become a clinically standard modality for the treatment of localized jawbone defects. Barrier membranes play an important role in this process by preventing soft tissue invasion outgoing from the mucosa and creating an underlying space to support bone growth. Different membrane types provide different biological mechanisms due to their different origins, preparation methods and structures. Among them, collagen membranes have attracted great interest due to their excellent biological properties and desired bone regeneration results to non-absorbable membranes even without a second surgery for removal. This work provides a comparative summary of common barrier membranes used in GBR, focusing on recent advances in collagen membranes and their biological mechanisms. In conclusion, the review article highlights the biological and regenerative properties of currently available barrier membranes with a particular focus on bioresorbable collagen-based materials. In addition, the advantages and disadvantages of these biomaterials are highlighted, and possible improvements for future material developments are summarized.

22 January 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MSMarie Luise Semmler
Marie Luise Semmler
Sander BekeschusSander Bekeschus
Sander Bekeschus
MSMirijam Schäfer
Mirijam Schäfer
TBThoralf Bernhardt
Thoralf Bernhardt
TFTobias Fischer
Tobias Fischer
LBLars Boeckmann
Lars Boeckmann
Recently, the potential use of cold atmospheric pressure plasma (CAP) in cancer treatment has gained increasing interest. Especially the enhanced selective killing of tumor cells compared to normal cells has prompted researchers to elucidate the molecular mechanisms for the efficacy of CAP in cancer treatment. This review summarizes the current understanding of how CAP triggers intracellular pathways that induce growth inhibition or cell death. We discuss what factors may contribute to the potential selectivity of CAP towards cancer cells compared to their non-malignant counterparts. Furthermore, the potential of CAP to trigger an immune response is briefly discussed. Finally, this overview demonstrates how these concepts bear first fruits in clinical applications applying CAP treatment in head and neck squamous cell cancer as well as actinic keratosis. Although significant progress towards understanding the underlying mechanisms regarding the efficacy of CAP in cancer treatment has been made, much still needs to be done with respect to different treatment conditions and comparison of malignant and non-malignant cells of the same cell type and same donor. Furthermore, clinical pilot studies and the assessment of systemic effects will be of tremendous importance towards bringing this innovative technology into clinical practice.

28 August 2021 in Redox Biology
Verified
Journal Article
Open access
Sander BekeschusSander Bekeschus
Sander Bekeschus
TWThomas von Woedtke
Thomas von Woedtke
Steffen EmmertSteffen Emmert
Steffen Emmert
ASAnke Schmidt
Anke Schmidt
Defective wound healing poses a significant burden on patients and healthcare systems. In recent years, a novel reactive oxygen and nitrogen species (ROS/RNS) based therapy has received considerable attention among dermatologists for targeting chronic wounds. The multifaceted ROS/RNS are generated using gas plasma technology, a partially ionized gas operated at body temperature. This review integrates preclinical and clinical evidence into a set of working hypotheses mainly based on redox processes aiding in elucidating the mechanisms of action and optimizing gas plasmas for therapeutic purposes. These hypotheses include increased wound tissue oxygenation and vascularization, amplified apoptosis of senescent cells, redox signaling, and augmented microbial inactivation. Instead of a dominant role of a single effector, it is proposed that all mechanisms act in concert in gas plasma-stimulated healing, rationalizing the use of this technology in therapy-resistant wounds. Finally, addressable current challenges and future concepts are outlined, which may further promote the clinical utilization, efficacy, and safety of gas plasma technology in wound care in the future.

1 July 2020 in Physics of Plasmas
Verified
Journal Article
Closed access
PDF file
TWThomas von Woedtke
Thomas von Woedtke
Steffen EmmertSteffen Emmert
Steffen Emmert
HMHans-Robert Metelmann
Hans-Robert Metelmann
SRStefan Rupf
Stefan Rupf
Klaus-Dieter WeltmannKlaus-Dieter Weltmann
Klaus-Dieter Weltmann
Plasma medicine is an innovative research field combining plasma physics, life science, and clinical medicine. It is mainly focused on the application cold atmospheric plasma (CAP) in therapeutic settings. Based on its ability to inactivate microorganisms but also to stimulate tissue regeneration, current medical applications are focused on the treatment of wounds and skin diseases. Since CAP is also able to inactivate cancer cells, its use in cancer therapy is expected to be the next field of clinical plasma application. Other promising applications are expected in oral medicine and ophthalmology. It is the current state of knowledge that biological CAP effects are mainly based on the action of reactive oxygen and nitrogen species supported by electrical fields and UV radiation. However, continuing basic research is not only essential to improve, optimize, and enlarge the spectrum of medical CAP applications and their safety, but it is also the basis for identification and definition of a single parameter or set of parameters to monitor and control plasma treatment and its effects. In the field of CAP plasma devices, research and application are currently dominated by two basic types: dielectric barrier discharges and plasma jets. Its individual adaptation to specific medical needs, including its combination with technical units for continuous and real-time monitoring of both plasma performance and the target that is treated, will lead to a new generation of CAP-based therapeutic systems.

Verified
Journal Article
Open access
PDF file
LFLu Fan
Lu Fan
YRYanru Ren
Yanru Ren
Steffen EmmertSteffen Emmert
Steffen Emmert
IVIvica Vučković
Ivica Vučković
Sanja StojanovićSanja Stojanović
Sanja Stojanović
Xin XiongXin Xiong
Xin Xiong
Synthetic bone substitute materials (BSMs) are becoming the general trend, replacing autologous grafting for bone tissue engineering (BTE) in orthopedic research and clinical practice. As the main component of bone matrix, collagen type I has played a critical role in the construction of ideal synthetic BSMs for decades. Significant strides have been made in the field of collagen research, including the exploration of various collagen types, structures, and sources, the optimization of preparation techniques, modification technologies, and the manufacture of various collagen-based materials. However, the poor mechanical properties, fast degradation, and lack of osteoconductive activity of collagen-based materials caused inefficient bone replacement and limited their translation into clinical reality. In the area of BTE, so far, attempts have focused on the preparation of collagen-based biomimetic BSMs, along with other inorganic materials and bioactive substances. By reviewing the approved products on the market, this manuscript updates the latest applications of collagen-based materials in bone regeneration and highlights the potential for further development in the field of BTE over the next ten years.